Cancer

Study: Ivermectin Combo Shows Possible Cancer Benefit

Is ivermectin a promising cancer treatment or was this a fatally flawed study?

Published 5 hours ago

Study: Ivermectin Combo Shows Possible Cancer Benefit

story

Above: Ivermectin tablets arranged in Jakarta, Indonesia, on Sept. 2, 2021. Image credit: Dimas Ardian/Bloomberg/Getty Images

The Spin

Right narrative

A real-world study of 197 cancer patients taking ivermectin and mebendazole found an 84.4% clinical benefit ratio, with nearly half reporting tumor regression or no evidence of disease at six months. The regimen was well-tolerated, affordable and grounded in extensive preclinical evidence showing multi-target anticancer mechanisms. Randomized trials are urgently needed to confirm what this prospective cohort already signals.

Nicolas Hulscher on X

Peter McCullough on X

The Focal Points on Substack

Left narrative

This ivermectin-cancer study is an anonymous self-reported survey with no control group, no imaging to confirm outcomes and a 38% dropout rate, conducted entirely by authors who financially benefit from selling the drugs studied. Every outcome measure is unverifiable, and patients were simultaneously receiving chemotherapy, radiation and surgery. The 84.4% "clinical benefit" figure is statistically meaningless given these fatal design flaws.

Skyler Johnson on X

Important Context on Substack Lead Stories